Cancer Genetics (CGIX) Reports Q3 EPS of $0.98 (Earlier)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cancer Genetics (CGIX) Halted on LUDP
November 20, 2019 10:05 AM ESTCancer Genetics (NASDAQ: CGIX) Halted on LUDP
... MoreCancer Genetics (CGIX) Climbs 220% After Earnings
November 20, 2019 8:59 AM ESTCancer Genetics (NASDAQ: CGIX), a $4.2 million market cap company that offers proprietary preclinical test systems, climbed 210% pre-open after reporting Q3 results.
... More